{"title":"单用罗哌卡因与两种不同剂量右美托咪定加罗哌卡因局部皮下浸润治疗腰麻剖宫产术后疼痛的比较。","authors":"Atefeh Ghosouri, Alireza Hoghooghy, Azim Honarmand, Arefeh Kabirzadeh","doi":"10.4103/abr.abr_253_24","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>In a cesarean section (CS), good postoperative pain management is of great importance. We assessed the effect of adding dexmedetomidine to ropivacaine 0.5% in CS patients with spinal anesthesia to assess its ability to enhance pain management.</p><p><strong>Materials and methods: </strong>This was a randomized controlled trial in Shahid Beheshti Hospital between 2022 and 2023 with the goal of assessing ropivacaine efficacy with and without dexmedetomidine on pain control after a CS. Spinal anesthesia was administered for all patients by using bupivacaine 0.5%. Before wound closure, patients were treated with analgesics. Group A received dexmedetomidine 1 µg/kg infiltrated subcutaneously, followed by ropivacaine 0.5% 3 mg/kg diluted with normal saline to 40 cc. Group B received dexmedetomidine 2 µg/kg, followed by ropivacaine 0.5% 3 mg/kg. The control group received ropivacaine 0.5% 3 mg/kg. A <i>P</i> value of < 0.05was regarded as significant.</p><p><strong>Results: </strong>The study groups exhibited significantly lower visual analog scale (VAS) pain scores. Specifically, group A showed significantly lower VAS scores than the controls, and group B also showed significantly lower VAS scores than group A. The VAS score after 24 hours of CS was, on average, 2.13 (SD = 0.16, 95% CI = [1.74, 2.52]) lower in group B compared to the control group and 1.1 (SD = 0.16, 95% CI = [0.71, 1.49]) lower than in group A (<i>P</i> < 0.05).</p><p><strong>Conclusions: </strong>Subcutaneous infiltration of dexmedetomidine with ropivacaine improves postoperative pain management more effectively than using ropivacaine alone. It is noteworthy that dexmedetomidine 2 µg/kg can improve pain after a CS more effectively than 1 µg/kg.</p>","PeriodicalId":94292,"journal":{"name":"Advanced biomedical research","volume":"14 ","pages":"52"},"PeriodicalIF":0.7000,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12165305/pdf/","citationCount":"0","resultStr":"{\"title\":\"Comparison of Local Subcutaneous Infiltration with Ropivacaine Alone and Two Different Doses of Dexmedetomidine Plus Ropivacaine for Postoperative Pain after Cesarean Section Under Spinal Anesthesia.\",\"authors\":\"Atefeh Ghosouri, Alireza Hoghooghy, Azim Honarmand, Arefeh Kabirzadeh\",\"doi\":\"10.4103/abr.abr_253_24\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>In a cesarean section (CS), good postoperative pain management is of great importance. We assessed the effect of adding dexmedetomidine to ropivacaine 0.5% in CS patients with spinal anesthesia to assess its ability to enhance pain management.</p><p><strong>Materials and methods: </strong>This was a randomized controlled trial in Shahid Beheshti Hospital between 2022 and 2023 with the goal of assessing ropivacaine efficacy with and without dexmedetomidine on pain control after a CS. Spinal anesthesia was administered for all patients by using bupivacaine 0.5%. Before wound closure, patients were treated with analgesics. Group A received dexmedetomidine 1 µg/kg infiltrated subcutaneously, followed by ropivacaine 0.5% 3 mg/kg diluted with normal saline to 40 cc. Group B received dexmedetomidine 2 µg/kg, followed by ropivacaine 0.5% 3 mg/kg. The control group received ropivacaine 0.5% 3 mg/kg. A <i>P</i> value of < 0.05was regarded as significant.</p><p><strong>Results: </strong>The study groups exhibited significantly lower visual analog scale (VAS) pain scores. Specifically, group A showed significantly lower VAS scores than the controls, and group B also showed significantly lower VAS scores than group A. The VAS score after 24 hours of CS was, on average, 2.13 (SD = 0.16, 95% CI = [1.74, 2.52]) lower in group B compared to the control group and 1.1 (SD = 0.16, 95% CI = [0.71, 1.49]) lower than in group A (<i>P</i> < 0.05).</p><p><strong>Conclusions: </strong>Subcutaneous infiltration of dexmedetomidine with ropivacaine improves postoperative pain management more effectively than using ropivacaine alone. It is noteworthy that dexmedetomidine 2 µg/kg can improve pain after a CS more effectively than 1 µg/kg.</p>\",\"PeriodicalId\":94292,\"journal\":{\"name\":\"Advanced biomedical research\",\"volume\":\"14 \",\"pages\":\"52\"},\"PeriodicalIF\":0.7000,\"publicationDate\":\"2025-05-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12165305/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advanced biomedical research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4103/abr.abr_253_24\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advanced biomedical research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/abr.abr_253_24","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
Comparison of Local Subcutaneous Infiltration with Ropivacaine Alone and Two Different Doses of Dexmedetomidine Plus Ropivacaine for Postoperative Pain after Cesarean Section Under Spinal Anesthesia.
Background: In a cesarean section (CS), good postoperative pain management is of great importance. We assessed the effect of adding dexmedetomidine to ropivacaine 0.5% in CS patients with spinal anesthesia to assess its ability to enhance pain management.
Materials and methods: This was a randomized controlled trial in Shahid Beheshti Hospital between 2022 and 2023 with the goal of assessing ropivacaine efficacy with and without dexmedetomidine on pain control after a CS. Spinal anesthesia was administered for all patients by using bupivacaine 0.5%. Before wound closure, patients were treated with analgesics. Group A received dexmedetomidine 1 µg/kg infiltrated subcutaneously, followed by ropivacaine 0.5% 3 mg/kg diluted with normal saline to 40 cc. Group B received dexmedetomidine 2 µg/kg, followed by ropivacaine 0.5% 3 mg/kg. The control group received ropivacaine 0.5% 3 mg/kg. A P value of < 0.05was regarded as significant.
Results: The study groups exhibited significantly lower visual analog scale (VAS) pain scores. Specifically, group A showed significantly lower VAS scores than the controls, and group B also showed significantly lower VAS scores than group A. The VAS score after 24 hours of CS was, on average, 2.13 (SD = 0.16, 95% CI = [1.74, 2.52]) lower in group B compared to the control group and 1.1 (SD = 0.16, 95% CI = [0.71, 1.49]) lower than in group A (P < 0.05).
Conclusions: Subcutaneous infiltration of dexmedetomidine with ropivacaine improves postoperative pain management more effectively than using ropivacaine alone. It is noteworthy that dexmedetomidine 2 µg/kg can improve pain after a CS more effectively than 1 µg/kg.